Cancer

Cancer is a disease in which cells in the body multiply out of control and spread to other parts of the body.

Under normal conditions, human cells form and multiply (through a process called cell division) to form new cells as they are needed by the body. When cells become old or damaged, they die and new cells replace them.

Sometimes the process does not follow this order and abnormal or damaged cells form and multiply when they should not. These cells may form tumours, which are lumps of tissue.

Tag Archive for: Cancer

International Lungcancer Symposium

International Lungcancer Symposium

Oncothermia is an adjuvant method for the treatment of cancers, as in the case of Lung Cancer. It stands out for being a non-invasive method that can be combined with radiotherapy and chemotherapy.

Oncothermia is present internationally in congresses and conferences. In these scientific meetings doctors make presentations to disseminate the results of clinical cases.

2nd International Symposium on lung cancer

On April 17, 2016, in Budapest, the 2nd International Symposium on Lung Cancer took place (2nd International Lungcancer Symposium). The conference was organized in different sections. Professor Szasz directed the section: “Oncothermia in Advanced Lung Cancer”, where he presented his latest research and clinical results.

Clinical trials: Oncothermia and Cancer

Ensayos clínicos: Oncothermia y Cáncer

Clinical trials: Oncothermia and Cancer.

Oncothermia is an active part of current medical research. There are several Clinical Trials, in patients with cancer, performed in different hospitals around the world.

Clinical trials are a basic tool for the development of drugs and medical devices, in order to improve the current treatment of diseases and develop health tools worldwide.

Clinicaltrials.gov is an internationally recognized web page, where researchers publish the latest clinical trials that are carried out in different hospitals around the world. Oncothermia is present on this website. We will inform you about the latest advances in Oncothermia and Cancer.

Clinical study of Oncothermia applied to a patient with malignant ascites

The clinical study “Oncothermia + intraperitoneal chemotherapy in malignant ascites: Phase II” (Local mEHT * + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT (OTMA-RII) of Prof. Pang, Clifford Hospital, Guangzhou, China) began to include patients in January 2014 and ended in March 2016. The research included two groups of 130 patients. The “experimental group” will be treated with: diet, Chinese herbal medicine and Oncothermia. Instead, the “control group” will be treated with chemotherapy.

We will be attentive to the conclusions of the study!

* Clinical trial “Oncothermia + intraperitoneal chemotherapy in malignant ascites: Phase II“

Oncothermia: its presence in the world

Oncothermia: its presence in the world

Oncothermia is a natural adjuvant and non-invasive method to treat cancer. It has now been distributed worldwide. It is present in 24 countries.

These are more than 180 facilities, including public hospitals and private clinics. It should be noted that more than 200,000 treatments are performed annually.

In Germany alone, Oncothermia equipment has been installed in 4 public hospitals, in addition to 80 private clinics. Among them the most relevant are:

  • Uni-Zentrum Naturheilkunde, Institute Universitäts Klinikum, Freiburg
  • Klinikum der LMU – München; Klinikum,Region Hannover
  • Krankenhaus Siloah Medizinische Klinik Hannover
  • Medizinische Versorgungszentren Altenburger
  • Institute of MikrotherapieWithen—Bochum

In Barcelona

The Barcelona Oncothermia Unit is equipped with the latest generation EHZ-2000 model, placing it as a local and global benchmark.

If you need more information, you can consult the different Oncothermia facilities by country.

,

Oncothermia receives the patent as a “tumor vaccine”

Oncothermia como patente cáncer

Oncothermia receives the patent as a “tumor vaccine”

This treatment alerts our immune system by checking the cancer cells.

The Oncothermia EHY-2000 plus device received the patent, US 20150217099 A1 in August 2015, describing this treatment as “a tumor vaccine”. It refers to “a vaccine” because it stimulates the immune system and radiofrequency promotes apoptosis or cell death of tumor cells.

Oncothermia is effective for the primary tumor and its metastases. Therefore, it has a local and systemic effect.

Procedure of action of the “vaccine”

The applied technique is called Modulated Electro-Hyperthermia (mEHT). The cancer cells in our body when treated with mEHT produce “heat shock proteins” when they are heated. This treatment alerts our immune system by checking the cancer cells. In this way, these cells are recognized by our immune system and eliminate them.

We all have approximately 1000 cancer cells that circulate in our body every day. Those with a weak immune system can develop a tumor.

In conclusion

For patients diagnosed with cancer, Oncothermia is an excellent option for immunotherapy to complement conventional treatments: surgery, chemotherapy or radiotherapy, in an integrative oncology framework.

You can obtain more information about the operation of Oncothermia for treatments in cancer patients through this link.

Oncothermia versus hyperthermia: cellular effects in complementary treatments of cancer

Oncothermia versus Hyperthermia: cellular effects in complementary cancer treatments.

Oncothermia is based on the Hyperthermia method, frequently used for cancer treatments. But unlike conventional Hyperthermia, Oncothermia, in addition to producing an absolute increase in the temperature of the deep tissue layers, also combines the action of the modulated electric field, with a carrier frequency of 13.56MHz, which is generated by two electrodes assets.

This electric field allows an absorption of energy in the extracellular fluid (ECM), and the imbalance and destructuration of the membrane of the cancer cells achieving important effects at only 38ºC.

Selective capacity of Oncothermia with respect to Hyperthermia

Microbiological studies have shown that cancerous tissues have a greater conductivity in relation to healthy tissues, due to metabolic differences. It is for this reason that the electric field tends to flow preferentially in the malignant tumor tissue, selecting the cells to be treated.

The natural activity of malignant cells is inhibited, dying by apoptosis, that is, by a natural process of cell death induced by the immune system without overloading toxins in the body; unlike necrosis, pathological cell death, produced in conventional hyperthermia.

Conclusion

While conventional hyperthermia disperses heat, oncothermia focuses on the tumor, captures cancer cells by the frequency they emit, focusing it and making it more effective.

If you wish, you can find more information about Oncotermia treatment on our website.

Oncothermia in combination with Radiotherapy exerts a radiosensitizing effect in lung cancer.

efecto radiosensibilizante en el Cáncer de PulmónOncothermia in combination with Radiotherapy exerts a radiosensitizing effect in lung cancer.

The sensitivity of tumors to radiotherapy and chemotherapy is increased by Oncothermia.

Oncothermia, also known as electro-hyperthermia, is a new treatment modality that allows for increased sensitivity to other treatments. It has been developed to overcome the problems of traditional hyperthermia by targeting malignant tissues.

A study was published in 2015 in the journal Experimental and Therapeutic Medicine. It reports the outcome of combined oncothermia and RT in a 75-year-old patient with stage IIIB non-small-cell lung cancer (NSCLC).

Due to the advanced age and the performance status of the patient, the combination of systemic chemotherapy and RT was deemed infeasible. Therefore, the patient instead decided to undergo oncothermia concurrently with definitive RT.

The RT was administered at a dose of 64.8 Gy in 36 fractions using a three-dimensional conformal plan technique. In this case, Oncothermia was started concomitantly with RT. And was performed for 60 min per session, two sessions per week, for a total of 12 sessions.

Follow-up computed tomography showed complete tumor response. And the patient was alive with no evidence of the disease 18 months after the completion of the treatment.

In conclusion, the present case report suggests that oncothermia combined with RT has former possessing radiosensitizing potential and no additional toxicities. May be it is a promising alternative for advanced-age and/or frail patients with locally advanced NSCLC.

In addition, you can find more information about lung cancer on our website.

Stage IV Kidney Cancer treated by Oncothermia and herbs

Stage IV Kidney Cancer (Wilms Tumor) treated by Oncothermia and herbs

[message_box title=”Wilms tumour is the most common cause of kidney cancer in childhood and adolescence.” color=”red”]It also carries a mortality rate of 7-8 in one million. The 5-year survival rate for kidney cancer is 77.2 – 87.5%. When Wilms tumour progresses, radiotherapy and chemotherapy are conventionally used as the only treatments.[/message_box]

Clinical case

A 17-year-old Korean woman was treated from October 25, 2014, until July 22, 2015 with an integrating medical treatment, in order to control the extent of her illness.

The integrative medical treatment included: oncothermia, thymosin-α1 and phytotherapy. Phytotherapy was administered in 8 ml. of inhalation of Soram nebulizer solution qd, Soramdan S 8 g po, Hangamdan S 1 g po, tid, Cheongjangtang 10-30 ml, and Spiam HC 8 g po. She received Oncothermia (2-3 times a week) and 1.6 mg of treatment with thymosin-α1 (Zadaxin) i.m.

Result

According to the result of the CT on July 15, 2015, the liver metastasis was no longer seen, while the lung metastasis remained stable without tumor progression.

Conclusion

In patterns of Wilms tumor progression after surgery and chemotherapy, integrative medical treatment can be significant for disease control.

Reference

Lee D, Kim SS, Seong S, Cho W, Yu H. Stage IV Wilms Tumor Treated by Korean Medicine, Hyperthermia and Thymosin-α1: A Case Report. Case Rep Oncol. 2016 Feb 20;9(1):119-25. doi: 10.1159/000443724. 

If you wish, you can find more information about clinical cases treated with Oncotermia on our website.

Effect of Oncothermia at the cellular level. Study in colorectal cancer xenografts

Effect of Oncothermia at the cellular level. Study in colorectal cancer xenografts

Researchers studied the effect of Oncothermia at the cellular level in the process of apoptosis in colorectal cancer cells.

The Department of Radiology of the Medicine and Pharmacy Faculty -University of Toyama, in Toyama, Japan- published in the journal CellStress and Chaperones (Springer) (Cell Stress Chaperones, 2015 Jan; 20 (1): 37-46 ) the results on the effect of Oncothermia in colorectal cancer cells.

Cell apoptosis

First of all, the use of modulated electrohyperthermia (mEHT) or Oncothermia, produces a modification of the electric field and the surrounding temperature of the tumor cell, leading to selective cell death (apoptosis) in malignant tumors without affecting healthy tissue. Certainly, this is possible due to the difference of a tumor cell compared with a healthy cell. Also, the tumor cell is characterized by high glycolysis, increased lactate production (Warburg effect) and reduced electrical impedance.

Oncothermia applied to colorectal cancer

Dr Andocs studied the effect of Oncothermia on HT29 xenografts of colorectal cancer (human colon cancer cells, inoculated in mice). Apoptosis caused by Oncothermia was mediated, predominantly, by the caspase cascade and the activation of the apoptosis inducing factor. The mEHT-related cell stresses studied 0-, 1-, 4-, 8-, 14-, 24-, 48-, 72-, 120-, 168- and 216-h. And post-treatment by focusing on damage-associated molecular pattern (DAMP) signals.

 Apoptosis response was after 4 hours from the treatment with Oncothermia. It was measured using the levels of messenger RNA (mRNA) levels of the “heat shock” proteins Hsp70 and Hsp90.

Results

After that, the treatment resulted in spatiotemporal occurrence of a DAMP protein signal sequence featured by the significant cytoplasmic to cell membrane translocation of calreticulin at 4 h, Hsp70 between 14 and 24 h and Hsp90 between 24- and 216-h post-treatment.

Also, the release of high-mobility group box1 protein (HMGB1) from tumor cell nuclei from 24-h post-treatment and its clearance from tumor cells by 48 h was also detected.

Conclusion

In conclusion, the results suggest that mEHT treatment can induce a DAMP-related signal sequence in colorectal cancer xenografts that may be relevant for promoting immunological cell death response, which need to be further tested in immune-competent animals.

To conclude, the next experimental phase, which is to replicate the study in immunocompetent animals, is necessary.

Further information

If you would like further information on Oncothermia applied to colon cancer, please visit the following link.

,

Oncothermia at the Congress of Radiotherapy Technicians (10-12 / 11/2017, Lisbon, Portugal)

Oncothermia at the Congress of Radiotherapy Technicians (10-12 / 11/2017, Lisbon, Portugal)

Filipe Cidade de Moura and Prof.András Szász

Oncothermia is an adjuvant treatment for cancer. It is present at an international level at events such as this congress and other conferences. At these scientific meetings, doctors, technicians and healthcare personnel give presentations to disseminate the results of clinical cases.

Congress in Lisboa

Therefore, on November 10-12, 2017, in Lisbon, took place the Congress of Radiotherapy Technicians (Congresso 2017art).

The congress was organized in different sections. Professor Szasz led the talk “Immunological effects with Oncothermia“, where he presented his latest research and results. Also, he detailed his studies on Oncothermia and the results in relation to the inhibitory effect on the natural activity of the malignant cells. Among other things he highlighted the stimulation of the patient’s immune response.

Objective of the research

Most of the radiation therapies act locally. The local control of the tumor is usually not enough for elongation of the survival time because the malignancy is systemic. The abscopal effect, together with immune-stimuli could extend the local method to systemic and could be effective against macro- and micrometastases, too. Our objective is presenting the abscopal effect of modulated electro-hyperthermia (mEHT, oncothermia).

References

https://www.justnews.pt/documentos/2015/image/file/17e/ProgramaCNART-2017.pdf

http://oncotherm.com/en/news-events/congresso-2017-art-profandras-szasz-was-invited-hold-lecture

Oncothermia combined with chemotherapy for the treatment of recurrent cervical cancer

Oncothermia combined with chemotherapy for the treatment of recurrent cervical cancer

Researchers compared the effect of Oncothermia combined with conventional chemotherapy versus chemotherapy alone in patients with cervical cancer.

Cáncer cérvix Oncothermia

Dr. Lee’s team, from Department of Radiation Oncology, Institute of Medical Sciences, Chonbuk Medical University, South Korea, has recently published in the journal Oncology Letters the results on the complementary use of Oncothermia in recurrent Cervix Cancer previously treated with radiotherapy.

The present study was performed to evaluate the effect of Oncothermia combined with conventional chemotherapy compared with chemotherapy alone on recurrent cervical cancer previously treated with irradiation.

Method

A total of 20 patients, aged 36-71 years, with cervical cancer were treated with chemotherapy. Of these, 18 patients were treated with chemotherapy combined with Oncothermia. In addition, the equipment used was: EHY2000 (Oncotherm GmbH, Troisdorf, Germany). And the frequency was 13.56 MHz, with the circular electrode diameter of 30 cm.

In addition, local metastases (including para-aortic lymph nodes and adjacent pelvic lymph nodes) were considered in the inclusion criteria of the study. Also, patients with distant metastases were excluded.

For the study, Oncothermia was applied 3 times a week for 60 minutes from the start of chemotherapy. A total of 36 sessions were carried out.

Results

The overall response (complete remission + partial remission + stable disease/progressive disease) to treatment was significantly greater in the group of patients who underwent chemotherapy combined with Oncothermia (P=0.0461). Then, Oncothermia was shown to be more effective in the treatment of local metastases (lymph nodes). No complications with the use of Oncothermia were reported.

Conclusion

In conclusion, in patients with recurrent cervical cancer treated with radiotherapy, the overall response rate to treatment is significantly higher in patients who combined chemotherapy with Oncothermia compared to those who only received chemotherapy.

Reference

Lee SY, Lee NR, Cho DH, Kim JS. Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation. Oncol Lett. 2017 Jul;14(1):73-78. doi: 10.3892/ol.2017.6117. Epub 2017 May 4. PMID: 28693137; PMCID: PMC5494813.